IPW
FDMT icon

Impact Partnership Wealth’s 4D Molecular Therapeutics FDMT Stock Holding History

Impact Partnership Wealth’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,123
Closed -$113K – 392
2025
Q4 		$113K Buy
15,123
+4,045
+37% +$41K 0.01% 352
2025
Q3 		$96.3K Buy
+11,078
New +$66.2K 0.01% 302
2023
Q3 		– Sell
-57
Closed -$1.03K – 1071
2023
Q2 		$1.03K Buy
+57
New +$1.05K ﹤0.01% 789

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Impact Partnership Wealth's FDMT Position: Q1 2026 in Review

Impact Partnership Wealth sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 15,123 shares — an estimated $113K sold.

Impact Partnership Wealth first reported a position in FDMT in Q2 2023 and held it in 3 quarters. The position peaked at $113K in Q4 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Impact Partnership Wealth reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Impact Partnership Wealth sold 15,123 4D Molecular Therapeutics shares in Q1 2026, an estimated $113K.
  • Impact Partnership Wealth first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 3 quarters.
  • Impact Partnership Wealth's 4D Molecular Therapeutics position peaked at $113K in Q4 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Impact Partnership Wealth's 13F filing for Q1 2026, filed 23 Apr 2026.